Ouch, Canada! Prexige Withdrawn From Yet Another Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Ottawa withdraws marketing authorization for Novartis’ troubled anti-inflammatory drug due to the potential for serious liver damage.
You may also be interested in...
Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review
EU’s Article 107 procedure was prompted by U.K. sanctions imposed in August after two Australian patients died from liver damage.
Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review
EU’s Article 107 procedure was prompted by U.K. sanctions imposed in August after two Australian patients died from liver damage.
No Big Surprise For Novartis: Prexige Is “Not Approvable” At FDA
Firm now plans to discuss path forward, which may include additional trials of the COX-2 inhibitor, with FDA, Novartis tells "The Pink Sheet" DAILY.